BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23042584)

  • 1. Consistency in the safety labeling of bioequivalent medications.
    Duke J; Friedlin J; Li X
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of FDA safety-related drug label changes in 2010.
    Lester J; Neyarapally GA; Lipowski E; Graham CF; Hall M; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):302-5. PubMed ID: 23280652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety information in drug labeling: a comparison of the USA, the UK, and Japan.
    Shimazawa R; Ikeda M
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):306-18. PubMed ID: 23355452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
    Rostron A
    Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 7. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 8. Trying times for generic medicines in the USA.
    Lancet; 2013 Mar; 381(9872):1072. PubMed ID: 23540840
    [No Abstract]   [Full Text] [Related]  

  • 9. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
    Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J
    Mod Healthc; 2014 Jun; 44(26):20-2. PubMed ID: 25134408
    [No Abstract]   [Full Text] [Related]  

  • 11. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 12. European Medicines Agency assesses safety reporting at Roche.
    Marshall H
    Lancet Oncol; 2012 Aug; 13(8):e331. PubMed ID: 23024993
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Mar; 77(54):16158-63. PubMed ID: 22479732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 16. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs.
    Kesselheim AS; Franklin JM; Avorn J; Duke JD
    BMJ Qual Saf; 2013 Sep; 22(9):727-34. PubMed ID: 23620531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing generic antiepileptic drugs: Issues and concerns for nurse practitioners.
    Barrett MW
    J Am Acad Nurse Pract; 2010 Jun; 22(6):300-4. PubMed ID: 20536627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 19. Multinational medicines--ensuring drug quality in an era of global manufacturing.
    Okie S
    N Engl J Med; 2009 Aug; 361(8):737-40. PubMed ID: 19692686
    [No Abstract]   [Full Text] [Related]  

  • 20. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
    Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
    BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.